Senti Biosciences is trading 12.51% down at $0.30 after a September 24, 2026 prospectus registered up to 25,555,024 shares for resale by selling securityholders. - The registered shares represent approximately 82.0% of common stock outstanding, creating substantial potential dilution and selling pressure. - The broader market is modestly higher, suggesting the decline is primarily company-specific. - Recent Celadon transaction filings add uncertainty around the company’s capital structure and strategic transition.